Revvityブログ
発見から治療までのイノベーションを促進
 
     
    
            
        Latest
      
    
    Optimizing functional genomics research tools by aligning their design with the ongoing evolution of the genome.
Functional Genomic Screening 
October 30, 2025  -  3  min read
       
      Disease Research
        Tending to urolithiasis: tackling kidney stone disease research for stone formers.
            October 30, 2025 -
            3 min read
          
          
         
       
       
      Assay Development Workflows
        Advancing therapeutic strategies for CSF1R-ALSP.
            October 17, 2025 -
            5 min read
          
          
         
      Cancer, Cell and Gene Therapy, Biologics
        Elucidating critical anti-tumor immunity pathways via imaging-based cytotoxicity assays.
            October 17, 2025 -
            4 min read
          
          
         
      NGS
        Blurring the line: lncRNAs as hidden encoders of micropeptides.
            October 17, 2025 -
            5 min read
          
          
         
      Physiological Model Solutions
        Revvity and AIM Biotech collaborate to accelerate 3D biology and drug discovery.
            October 16, 2025 -
            2 min read
          
          
         
      NGS
        Circular RNAs as stable age and experience markers: new insights from Drosophila.
            October 16, 2025 -
            2 min read
          
          
         
      Neurodegeneration
        Landmark Huntington’s gene therapy success brings promise for neuroscience research.
            October 14, 2025 -
            2 min read
          
          
         
      Biomarker Detection
        Biomarker discovery in the era of multi-omics.
            September 25, 2025 -
            3 min read
          
          
         
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                  